Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer

Peeters, M; Oliner, K; Price, T; Cervantes, A; Sobrero, A; Ducreux, M; Hotko, Y; André, T; Chan, E; Lordick, F; Punt, C; Strickland, A; Wilson, Gregory; Ciuleanu, T; Roman, L; Van Cutsem, E; He, P; Yu, H; Koukakis, R; Terwey, J; Jung, A; Sidhu, R; Patterson, S

Affiliation

Antwerp University Hospital and University of Antwerp, Edegem, Belgium.

Issue Date

2015-12-15

Metadata

Show full item record

Abstract

We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials.gov, NCT0039183).

Citation

Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. 2015, 21 (24):5469-79 Clin Cancer Res

Journal

Clinical Cancer Research

URI

http://hdl.handle.net/10541/600544

DOI

10.1158/1078-0432.CCR-15-0526

PubMed ID

26341920

Type

Article

Language

ISSN

1078-0432

Collections

All Christie Publications